In this episode, we sit down with Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx, the pioneering biotech company behind a groundbreaking blood test that could change the future of ovarian cancer detection.
Ovarian cancer is notoriously difficult to diagnose early—and that delay often proves deadly. Oriana shares how AOA Dx is leveraging lipid and protein biomarkers and cutting-edge science to create a non-invasive, accurate, and early-stage detection test for one of the most deadly cancers affecting women.
